News Release

2022.07.07 lR Information

FY02/2023 Q1 Results Earnings Release Presentation

2022.06.20 Ethical Drugs

Notification of approval for manufacturing and marketing approval of the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU_® Tapes (Transdermal, pain treatment NSAID patch, development code: HP-3150) in Japan Hisamitsu

2022.05.26 Management and Personnel

Executive Appointments

2022.05.18 Other

Salonpas_® Named the World’s No.1 OTC Topical Analgesic Patch Brand for the Sixth Consecutive Year

2022.04.21 Research and Development

Notification of application for manufacturing and marketing approval of HP-5070 (primary palmar hyperhidrosis treatment drug) in Japan

2022.04.07 Other

Notice regarding humanitarian support for Ukraine

2022.04.07 Management and Personnel

Executive Appointments

2022.04.07 lR Information

FY02/2022 Q4 Results Earnings Release Presentation

2022.03.31 Other

Acquisition of Shares of AYM HD

2022.03.23 lR Information

Notice regarding Revision of Earnings Forecast

2022.03.23 Subsidiaries and Affiliated Companies

Noven Pharmaceuticals, Inc. press release : FDA Approves Once-Daily XELSTRYM™ (dextroamphetamine) Transdermal System, CII, for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients 6 Years and Older

2022.01.14 lR Information

Notice regarding Results and Completion of Acquisition of Treasury Shares

2022.01.13 lR Information

FY02/2022 Q3 Results Earnings Release Presentation